Patents Examined by Bridget E. Bunner
  • Patent number: 12286650
    Abstract: The purpose of the present invention is to provide a set of two polypeptides for use in light-dependent genetic recombination in which the N-terminal side fragment and the C-terminal side fragment of a Cre protein having an amino acid sequence of SEQ ID NO: 1 respectively bind to two proteins light-dependently forming a dimer.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: April 29, 2025
    Assignee: The University of Tokyo
    Inventor: Moritoshi Sato
  • Patent number: 12275795
    Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.
    Type: Grant
    Filed: September 21, 2022
    Date of Patent: April 15, 2025
    Assignee: NOVARTIS AG
    Inventors: Aida Abujoub, John Blankenship, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Haihui Lu
  • Patent number: 12269873
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: April 8, 2025
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Kathrin S. Michelsen, Stephan R. Targan
  • Patent number: 12269877
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: April 8, 2025
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, Jr., Jeno Gyuris
  • Patent number: 12269878
    Abstract: Antibodies specific to Notch4 and related methods of treating conditions such as airway inflammation.
    Type: Grant
    Filed: April 30, 2024
    Date of Patent: April 8, 2025
    Assignee: Alcea Therapeutics, Inc.
    Inventor: Fortunato Ferrara
  • Patent number: 12269859
    Abstract: The disclosure provides synthetic immune receptors (SIRs), nucleic acids encoding the SIRs, methods of making and using the SIRs, in, for example, adoptive cell therapy.
    Type: Grant
    Filed: December 2, 2017
    Date of Patent: April 8, 2025
    Assignee: Angeles Therapeutics, Inc.
    Inventor: Preet M. Chaudhary
  • Patent number: 12269879
    Abstract: A humanized antibody specific for CD22 and a chimeric antigen receptor using the same, and, in some aspects, a chimeric antigen receptor including the antibody or a CD19×CD22 antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition including the same for preventing or treating a disease mediated by B cells.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: April 8, 2025
    Assignee: INNOBATION BIO CO., LTD.
    Inventors: Seung Koo Kim, Ki Tae Kim
  • Patent number: 12258385
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: March 25, 2025
    Assignee: Janssen Biotech, Inc.
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 12251403
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: March 18, 2025
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Patent number: 12252541
    Abstract: Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: March 18, 2025
    Assignee: ABL BIO INC.
    Inventors: Kyungjin Park, Hyejin Chung, Kyeongsu Park, Yangsoon Lee, Mikyung Chang, Jaehyoung Jeon, Youngkwang Kim, Junhyun Jeong, Jiseon Yoo, Yeunju Kim, Donghoon Yeom, Eunjung Kim, Bora Lee, Jinwon Jung
  • Patent number: 12234285
    Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: February 25, 2025
    Assignees: XOMA (US) LLC, MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
  • Patent number: 12234293
    Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
    Type: Grant
    Filed: June 22, 2022
    Date of Patent: February 25, 2025
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Sanjay Khandekar, Patrick Mayes, Joanna Opalinska
  • Patent number: 12226459
    Abstract: The present invention relates to a use of collagen hydrolysate after intensive care unit (ICU) stay. The collagen hydrolysate improves the recovery and prevents and/or treats post intensive care syndrome (PICS) after ICU stay. The collagen hydrolysate is preferably administered as a supplement in the context of ICU stay and/or PICS. Collagen hydrolysate is generally-accepted to be safe and therefore can be taken as a preventive and long-term measure.
    Type: Grant
    Filed: August 30, 2023
    Date of Patent: February 18, 2025
    Assignee: ROUSSELOT B.V.
    Inventors: Barbara De Klerk-Engels, Elien Monique Gevaert, Praneeth Reddy Kuninty, Janne Prawitt, Nicolina Virgilio
  • Patent number: 12227578
    Abstract: An atlas of intestinal epithelial cells, intestinal epithelial stem cells and intestinal immune cells identifies new cell populations, markers, networks, and responses to stimuli. Intestinal T cells drive intestinal epithelial cell differentiation and activity. Accordingly, disclosed are methods of modulating intestinal epithelial cell differentiation, maintenance and/or function, related methods for the treatment of disease, including IBD. Also disclosed are methods and kits for identifying cell types, their differentiation, homeostasis and activation.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: February 18, 2025
    Assignees: The Broad Institute, Inc., Massachussetts Institute of Technology, The General Hospital Corporation
    Inventors: Adam Haber, Moshe Biton, Rebecca H. Herbst, Karthik Shekhar, Christopher Smillie, Orit Rozenblatt-Rosen, Ramnik Xavier, Aviv Regev, Jose Ordovas-Montanes, Alexander K. Shalek, Noga Rogel
  • Patent number: 12228579
    Abstract: A method of determining a management course for treating a subject showing symptoms of a disease is disclosed. The method comprises measuring the TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is below a predetermined amount, the subject is treated as a high-risk patient.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: February 18, 2025
    Assignee: MeMed Diagnostics Ltd.
    Inventors: Eran Eden, Kfir Oved, Assaf Cohen-Dotan, Roy Navon, Olga Boico, Meital Paz
  • Patent number: 12221488
    Abstract: Provided herein are an apelin receptor (APJ) antibody and its fusion protein with Elabela. Also provided herein is a pharmaceutical composition of a fusion protein with APJ antibody and Elabela, and use thereof in treating, preventing, or alleviating one or more symptoms of pulmonary arterial hypertension, pulmonary hypertension or one or more symptoms of heart failure.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: February 11, 2025
    Inventors: Cheng Zhang, Lei Sun, Rongzhu Wang, Chenjiang Yao, Xiaofeng Wang, Hua Zhang, Shuqian Jing
  • Patent number: 12220450
    Abstract: The present invention provides a novel complex for use in the prevention and/or treatment of colorectal cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of colorectal cancer, such as a pharmaceutical compositions and vaccines are provided.
    Type: Grant
    Filed: August 9, 2021
    Date of Patent: February 11, 2025
    Assignee: Amal Therapeutics SA
    Inventors: Madiha Derouazi, Elodie Belnoue
  • Patent number: 12214048
    Abstract: The present invention provides a combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, at least one antigen or antigenic epitope, and a TLR peptide agonist for use in medicine, in particular in the prevention and/or treatment of cancer. Moreover, the present invention also provides compositions, such as a pharmaceutical compositions and vaccines, which are useful in medicine, for example in the prevention and/or treatment of cancer.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: February 4, 2025
    Assignee: AMAL THERAPEUTICS SA
    Inventors: Madiha Derouazi, Elodie Belnoue
  • Patent number: 12215136
    Abstract: The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.
    Type: Grant
    Filed: April 4, 2023
    Date of Patent: February 4, 2025
    Assignee: The Catholic University of Korea Industry—Academic Cooperation Foundation
    Inventors: Tai Gyu Kim, Hyun Jung Sohn, Su Eon Kim
  • Patent number: 12209254
    Abstract: The present invention relates generally to the identification and isolation of human otic progenitor cells. More specifically, the present invention relates to a method of using cell markers to identify and isolate human otic progenitor cells from a mixed population of cells, methods of enrichment and production of human otic progenitor cells, and associated kits for use in identification and/or isolation of human otic progenitor cells, wherein the cell markers are selected from SSEA1 (CD15), disialoganglioside GD3, TRA-2-49 (liver/bone/kidney alkaline phosphatase), SSEA4, ganglioside GD2 and CD141.
    Type: Grant
    Filed: March 13, 2023
    Date of Patent: January 28, 2025
    Assignee: THE UNIVERSITY OF SHEFFIELD
    Inventors: Carlos Marcelo Nicolas Rivolta, Sarah Louise Boddy